JAC Advance Access published online on May 12, 2008
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkn194
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original research |
BSAC standardized disc susceptibility testing method (version 7)
Department of Microbiology, City Hospital NHS Trust, Birmingham B18 7QH, UK
Received 14 March 2008; returned 30 March 2008; revised 1 April 2008; accepted 2 April 2008
* Corresponding author. Tel: +44-121-507-5693; Fax: +44-121-507-5521; E-mail: jenny.andrews{at}swbh.nhs.uk
The changes that have been made to the previous version of the recommendations (version 6) are as follows: medium and incubation condition for testing Acinetobacter spp. (Tables 1 and 6); use of cefoxitin as an indicator antibiotic for detecting methicillin/oxacillin/cefoxitin resistance in coagulase-negative staphylococci (Tables 1, 6 and 11); MIC breakpoint for co-trimoxazole based on the trimethoprim concentration in a 1:19 combination with sulfamethoxazole (Tables 7, 10, 11, 12, 15, 16 and 19); advice on the use of azithromycin for the treatment of infections with Salmonella typhi (footnote to Table 7); amendment to the recommendation for cefuroxime for the treatment of infections with Proteus mirabilis (footnote Table 7); MIC and zone diameter breakpoints for Stenotrophomonas maltophilia only (Table 10); MIC breakpoints for daptomycin (Tables 11 and 15); clarification for staphylococci that the neomycin zone diameter breakpoints are for topical use only and differentiate the isolates outside the ‘wild-type’ population in Table 11; clarification for β-haemolytic streptococci that the linezolid zone diameter breakpoints relate to an MIC breakpoint of 2 mg/L as no data for the intermediate category are currently available (Table 15); clarification that strains with reduced susceptibility to fluoroquinolones give no zone of inhibition with a 30 µg nalidixic acid disc (Tables 16 and 21); erythromycin is no longer used for therapy of Neisseria gonorrhoeae, but may be tested for epidemiological purposes (Table 17); clarification that the ciprofloxacin zone diameter breakpoint for Neisseria meningitidis relates to the MIC breakpoint of 0.03 mg/L as no data for the intermediate category are currently available; clarification that the ciprofloxacin zone diameter breakpoints for Campylobacter spp. relate to an MIC breakpoint of 0.5 mg/L as no data for the intermediate category are currently available; clarification that for ciprofloxacin and vancomycin zone diameter breakpoints for coryneform organisms relate to an MIC breakpoint of 0.5 and 4 mg/L, respectively, as no data for the intermediate category are currently available; MIC and zone diameter breakpoints for Gram-negative rods isolated from urinary tract infections have been expanded to include Klebsiella spp.; and a definition of coliforms is also included (Table 26).
Key Words: breakpoints , disc testing , MICs
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Wootton, T. R. Walsh, L. Macfarlane, and R. A. Howe Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins J. Antimicrob. Chemother., November 13, 2009; (2009) dkp404v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Ricci and L. J. V. Piddock Only for substrate antibiotics are a functional AcrAB-TolC efflux pump and RamA required to select multidrug-resistant Salmonella Typhimurium J. Antimicrob. Chemother., September 1, 2009; 64(3): 654 - 657. [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. Gordon and D. W. Wareham Failure of the MicroScan WalkAway System To Detect Heteroresistance to Carbapenems in a Patient with Enterobacter aerogenes Bacteremia J. Clin. Microbiol., September 1, 2009; 47(9): 3024 - 3025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-H. Su, T.-L. Wu, A.-J. Kuo, J.-H. Chia, and C.-H. Chiu Antimicrobial susceptibility of Streptococcus pneumoniae at a university hospital in Taiwan, 2000-07: impact of modified non-meningeal penicillin breakpoints in CLSI M100-S18 J. Antimicrob. Chemother., August 1, 2009; 64(2): 336 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Ricci and L. J. V. Piddock Ciprofloxacin selects for multidrug resistance in Salmonella enterica serovar Typhimurium mediated by at least two different pathways J. Antimicrob. Chemother., May 1, 2009; 63(5): 909 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-L. Lu, M. Doumith, D. M. Livermore, T.-P. Chen, and N. Woodford Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase J. Antimicrob. Chemother., April 1, 2009; 63(4): 641 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Bean and D. W. Wareham Paradoxical effect of 1-(1-naphthylmethyl)-piperazine on resistance to tetracyclines in multidrug-resistant Acinetobacter baumannii J. Antimicrob. Chemother., February 1, 2009; 63(2): 349 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore and P. M. Tulkens Temocillin revived J. Antimicrob. Chemother., February 1, 2009; 63(2): 243 - 245. [Abstract] [Full Text] [PDF]
|
|